

N Category	Number of tumor-involved regional lymph nodes	Presence of in-transit, satellite and/or microsatellite metastases	T Category								
			T0	T1a	T1b	T2a	T2b	T3a	T3b	T4a	T4b
			No evidence of primary tumor	<0.8 mm without ulceration	<0.8 mm with ulceration or 0.8-1.0 mm with or without ulceration	>1.0-2.0 mm without ulceration	>1.0-2.0 mm with ulceration	>2.0-4.0 mm without ulceration	>2.0-4.0 mm with ulceration	>4.0 mm without ulceration	>4.0 mm with ulceration
N0	No regional metastases detected	No	-	IA	IA	IB	IIA	IIA	IIB	IIB	IIC
N1a	1 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N1b	1 clinically detected	No	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N1c	No regional lymph node disease	Yes	IIIB	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2a	2 or 3 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIA	IIIA	IIIA	IIIB	IIIB	IIIC	IIIC	IIIC
N2b	2 or 3, at least 1 of which was clinically detected	No	IIIC	IIIB	IIIB	IIIB	IIIB	IIIB	IIIC	IIIC	IIIC
N2c	1 clinically occult or clinically detected	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC
N3a	≥4 clinically occult (i.e., detected by SLN biopsy)	No	-	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3b	≥4, at least 1 of which was clinically detected, or the presence of any number of matted nodes	No	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID
N3c	≥2 clinically occult or clinically detected and/or presence of any number of matted nodes	Yes	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIIC	IIID

**T0** — no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma); **Tis** — melanoma in situ; **Tx** — thickness cannot be assessed. (Tis and Tx are not included in the table but are part of the staging system.) **Nx** — Regional nodes not assessed (e.g., SLN biopsy not performed, regional nodes previously removed for another reason). **Exception:** pathological N category is not required for T1 melanomas, use clinical N information. (If an SLNB was performed, the results can and *should* be used for pathological evaluation.)

**Table 2. AJCC Eighth Edition T Category, N Category and Pathological Stage Groups for Stages I to III Cutaneous Melanoma<sup>a,b</sup>**

<sup>a</sup>Adapted and used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the *AJCC Cancer Staging Manual, Eighth Edition*, New York: Springer International Publishing, 2017 (Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: Amin AB, Edge SB, Greene, FL, et al. (Eds.) *AJCC Cancer Staging Manual, Eighth Edition*, New York: Springer; 2017:563-585).<sup>3</sup>

<sup>b</sup>Adapted and used with permission from Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the *AJCC Cancer Staging Manual, Eighth Edition*. *CA Cancer J Clin* 2017; 67:472-491.<sup>4</sup>